Antineoplastic Agents: Cytotoxic Agents: Alkylating Agents
OLEUK1 “Leukeran tablet” 2 mg/tab
適應症：惡性淋巴瘤、濾泡性淋巴瘤。
Usual dose:
CLL: 0.1-0.2 mg/kg/day PO for 3-6 wks, continuous therapy: 0.03-0.1 mg/kg/day PO, intermittent, twice/wk, or once/mon, pulse course: single dose of 0.4 mg/kg PO, increase dose by 0.1 mg/kg to produce mild hematologic toxicity, until control of lymphocytosis or toxicity, high dose therapy: 30 mg/m2 PO once q2w has been used.
Lymphomas, malignant: 0.1-0.2 mg/kg/day PO for 3-6 wk, continuous therapy, 0.03-0.1 mg/kg/day PO, high dose therapy, 30 mg/m2 PO once q2w has been used.
Nephrotic syndrome: 100-200 mcg/kg/day PO, in a single dose, for eight to 12 wks.
Dose adjustment:
Hematologic: (hypoplastic bone marrow or lymphocytic infiltration of bone marrow): max. 0.1 mg/kg/day.
Adverse effect:
Acute pneumonitis, allergic reactions, erythema multiforme, skin reactions, stevens-Johnson syndrome, toxic epidermal necrolysis, hallucinations, seizures, peripheral neuropathy, hepatotoxicity, infertility, irreversible bone marrow failure, myelosuppression, leukemia, secondary malignancies.